Cytek Biosciences (CTKB) Projected to Post Earnings on Wednesday

Cytek Biosciences (NASDAQ:CTKB) will likely be releasing its Q3 2025 results after the market closes on Wednesday, November 5th. Analysts expect Cytek Biosciences to post earnings of $0.01 per share and revenue of $51.4880 million for the quarter. Interested persons may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Cytek Biosciences (NASDAQ:CTKB) last released its quarterly earnings data on Tuesday, November 28th. The company reported $0.04 earnings per share for the quarter. Cytek Biosciences had a negative net margin of 3.27% and a negative return on equity of 1.66%. The business had revenue of $40.48 million during the quarter.

Cytek Biosciences Trading Up 2.1%

Cytek Biosciences stock opened at $3.90 on Monday. Cytek Biosciences has a 1-year low of $2.37 and a 1-year high of $7.63. The firm has a market capitalization of $496.16 million, a price-to-earnings ratio of -78.00 and a beta of 1.33. The firm has a 50 day simple moving average of $3.93 and a 200 day simple moving average of $3.60.

Institutional Trading of Cytek Biosciences

Hedge funds have recently made changes to their positions in the stock. Federated Hermes Inc. lifted its holdings in shares of Cytek Biosciences by 150.9% during the 2nd quarter. Federated Hermes Inc. now owns 7,221 shares of the company’s stock worth $25,000 after acquiring an additional 4,343 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Cytek Biosciences during the 2nd quarter worth $889,000. Invesco Ltd. lifted its holdings in shares of Cytek Biosciences by 2.0% during the 2nd quarter. Invesco Ltd. now owns 343,659 shares of the company’s stock worth $1,168,000 after acquiring an additional 6,706 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Cytek Biosciences by 199.6% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 144,252 shares of the company’s stock worth $490,000 after acquiring an additional 96,098 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Cytek Biosciences during the 2nd quarter worth $84,000. 69.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on CTKB shares. Zacks Research upgraded shares of Cytek Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Cytek Biosciences in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.60.

Cytek Biosciences Company Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.